|
Bioequivalence of Diltiazem retard |
|
Bioequivalence of Digoxin |
|
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I |
|
Bioequivalence of Clopidogrel |
|
Chitosan Unguent in burned patients |
|
Community intrevention trial with VCN7-T in pediatric population, 2017-2021 (NeumoEfect) |
|
Bioequivalence of diclofenac sodium retard |
|
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension |
|
Bioequivalence of Abacavir |
|
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
|
Bioactive formulation to treat osteoarthritis |
|
Homeostec for chronic arthritis |
|
Phenamate in the treatment of prostate cancer |
|
Biomodulin T Intramuscular for Thymus Hypoplasia in Children. Phase III |
|
CENTAURO-4 Study |
|
Nimotuzumab-pancreatic cancer-adults-Phase IV. |
|
HEBERBIOVAC HB vaccine to reference material. |
|
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II. |
|
Hepatotoxicity by drugs |
|
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors |
